ArticleFEMS microbiology letters2025
Deciphering the microbiota compositions of complex biofilms from hospital and domestic settings across Estonia, Germany, and the United Kingdom.
Article in FEMS microbiology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Currently, there is a limited understanding of the microbiota composition of complex biofilms, in particular describing the abundance of bacterial genera, fungi, and yeasts with reference to the One Health axes. As a starting point, describing the microbiota found in these settings would begin to describe the nature of any biological hazards present and facilitate development of strategies to limit transmission and the spread of infection. Furthermore, using this approach, suitable interventional measures could then be tested in the laboratory-scale model for their efficacy and then applied in situ. COMplex Biofilms and AMR Transmission (COMBAT) is a consortium of research teams that studied the application of next-generation sequencing (NGS) strategies to identify bacterial, fungal, and yeast species present in selected biofilms recovered from drain settings found in domestic and hospital settings in four geographical regions. Findings from this study extended our understanding of the bacterial, fungal, and yeast abundances in these sample biofilms and how they may change following enrichment. A VSEARCH-based high-resolution clustering approach was implemented to full-length 16S rRNA (FL-16S) sequencing reads to generate near-ASV operational units, enabling detailed characterization of the microbial communities within complex biofilms. This analytical framework provides the basis for testing interventional measures at the laboratory scale that could be implemented to reduce risk to the One Health axes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.